CompanyDeals

Amoytop Biotech Inks $445M Deal with Aligos for China Rights to Novel Hepatitis B Capsid Modulator Pevifoscorvir

CompanyDrug

Changchun High & New Tech Gains NMPA Clearance for GenSci136 Phase I/II Trial in Generalized Myasthenia Gravis

CompanyDeals

Yifan Pharma Expands European Footprint, Licenses Long-Acting G-CSF Efbemalenograstim Alfa to Italy’s Molteni Farmaceutici

CompanyDeals

GE HealthCare and DeepHealth Expand Global Partnership to Advance AI-Powered Mammography Solutions

Betta Pharmaceuticals Partners with Eversana for US Commercialization of Ensartinib in ALK+ NSCLC
CompanyDeals

Betta Pharmaceuticals Partners with Eversana for US Commercialization of Ensartinib in ALK+ NSCLC

Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui's Global GLP-1 Portfolio
CompanyDeals

Kailera Therapeutics Debuts on Nasdaq with $625M IPO, Backed by Hengrui’s Global GLP-1 Portfolio

WinHealth Pharma Secures NMPA Approval for Korsuva (Difelikefalin) to Treat CKD-Associated Pruritus in Chinese Hemodialysis Patients
CompanyDrug

WinHealth Pharma Secures NMPA Approval for Korsuva (Difelikefalin) to Treat CKD-Associated Pruritus in Chinese Hemodialysis Patients

Company

RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China's Molecular Diagnostics Growth
CompanyDeals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

CompanyDrug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

CompanyDrug

Sino Biopharmaceutical Initiates Phase III Trial of LM-302 ADC Combined with Anti-PD-1 for CLDN18.2-Positive Gastric Cancer